Key Record Dates
| ClinicalTrials.gov Identifier: | NCT01903993 |
|---|---|
| Brief Title: | A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR" |
| First Submitted : | July 17, 2013 |
| First Submitted that Met QC Criteria : | July 17, 2013 |
| First Posted : | July 19, 2013 (Estimate) |
| Results First Submitted : | November 16, 2016 |
| Results First Submitted that Met QC Criteria : | April 24, 2017 |
| Results First Posted : | May 23, 2017 |
| Certification/Extension First Submitted : | June 15, 2016 |
| Certification/Extension First Submitted that Met QC Criteria : | June 16, 2016 |
| Certification/Extension First Posted : | June 20, 2016 (Estimate) |
| Last Update Submitted that Met QC Criteria : | September 10, 2019 |
| Last Update Posted : | October 2, 2019 |